RHYTHM PHARMACEUTICALS INC's ticker is RYTM and the CUSIP is 76243J105. A total of 147 filers reported holding RHYTHM PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.18 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $14,970,025 | +23.5% | 653,000 | -11.2% | 4.87% | +68.0% |
Q2 2023 | $12,120,150 | -7.6% | 735,000 | 0.0% | 2.90% | -26.2% |
Q1 2023 | $13,112,400 | -38.7% | 735,000 | 0.0% | 3.93% | -47.2% |
Q4 2022 | $21,403,200 | +7.9% | 735,000 | -9.3% | 7.44% | -9.2% |
Q3 2022 | $19,845,000 | +1221.2% | 810,000 | +123.8% | 8.20% | +1110.6% |
Q2 2022 | $1,502,000 | -56.1% | 362,000 | +214.8% | 0.68% | +51.5% |
Q4 2020 | $3,419,000 | +34.8% | 115,000 | +4.1% | 0.45% | -10.2% |
Q4 2019 | $2,537,000 | +127.9% | 110,500 | +188.5% | 0.50% | +39.9% |
Q4 2017 | $1,113,000 | – | 38,300 | – | 0.36% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
COMMODORE CAPITAL LP | 2,075,000 | $47,569,375 | 5.56% |
NEA Management Company, LLC | 2,909,956 | $66,710,741 | 5.15% |
Opaleye Management Inc. | 653,000 | $14,970,025 | 4.87% |
Frazier Life Sciences Management, L.P. | 2,371,304 | $54,362,144 | 3.61% |
VR Adviser, LLC | 1,090,000 | $24,988,250 | 2.63% |
RA Capital Management | 5,676,067 | $130,123,836 | 2.56% |
Samsara BioCapital, LLC | 345,293 | $7,915,842 | 2.42% |
SILVERARC CAPITAL MANAGEMENT, LLC | 260,537 | $5,972,811 | 1.81% |
Logos Global Management LP | 400,000 | $9,170,000 | 1.22% |
Cormorant Asset Management, LP | 850,000 | $19,486,250 | 1.14% |